Company news

Biohaven Ltd. news in 2026

Biohaven Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting

November 5, 2026

Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results

October 29, 2026

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

September 28, 2026

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

August 27, 2026

Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload

July 20, 2026

Biohaven Announces Scientific Leadership Transitions

July 9, 2026

Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator

June 30, 2026

Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease

June 29, 2026

Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation

June 1, 2026

Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile

May 26, 2026

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results

May 4, 2026

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

March 19, 2026

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

March 2, 2026

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

January 7, 2026

Decks in 2026